<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160619028528N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-29</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of mobile application-based educational intervention on promoting the knowledge of vulnerable women to human papillomavirus (HPV): a randomized controlled clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>The effect of mobile application-based educational intervention on promoting the knowledge of vulnerable women to human papillomavirus (HPV)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61291</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: Blocked random allocation method will be used for random assignment of samples to two intervention groups and control group (routine care). For this purpose, quadruple blocks will be considered. The six blocks may be TCTTCC, CTTC, CTCT, CCTT, TCTC, TCCT, with T being for the intervention group and C for the control group. The randbetween function in Excel will be used to randomly select blocks. Production numbers will be between 1 and 6 and will be selected based on the production number of the desired block and all 4 samples will be assigned to the intervention and control group, Blinding description: Due to the nature of the intervention, it will not be possible to keep participants blind during the intervention process. Blinding will take place at the level of the responsible researcher. In this way, the researcher will not be aware of how the individuals are randomized to the intervention and control groups. Also, in order to control the bias at the level of the evaluator (detection bias), the blinding process will be performed on the people who are responsible for collecting information and analyzing the data.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: human papillomavirus (HPV). Condition 2: Anogenital warts.</hc_freetext>
      <i_freetext>Intervention 1: This intervention is based on improving the knowledge of human papillomavirus as a first outcome and promoting the attitude and practice of vulnerable women as a secondary outcome through the mobile application. The content of the application has been prepared by a master's student in midwifery counseling. The research team includes a reproductive health specialist, a reproductive epidemiologist, a sexual health specialist, a psychiatrist, and a midwifery counseling student. After randomly assigning, the intervention group receives the application installation link, and after installing the application on the smartphone, users self-learning for a month. After a month, the application is automatically deactivated and users' access to the app content is cut off. Educational objectives are classified into three areas: affective, psychomotor, and cognitive. In the field of cognition, users are expected to learn about the nature of the HPV virus, its abbreviation, how it is transmitted, its prevalence in vulnerable women, preventive behaviors, the HPV vaccine, and high-risk behaviors after one month. In the field of ​affective, participants are expected to become familiar with common but incorrect beliefs and attitudes and replace them with the right attitudes.In the field of psychomotor, we expect vulnerable women to express behavioral goals that they have learned cognitively about preventive behaviors as behavioral intentions or to seek prevention and treatment if they have a midwife or specialist. The training framework will be implemented through this software in the method of repeated learning. In this context, users will receive a single content using a variety of methods, in simple language, understandable to the target group, and attractive to gradually reinforce the behavioral intent in them. The educational content before loading on the application will be evaluated by the panel of experts, scientifically, literary, and the opinion of the same audience group. Post-loading evaluation: Educational content after loading on the application by two groups of hardware technicians and the matched audience group is evaluated. The effect of the application on improving the outcome (knowledge about human papillomavirus) will be calculated through indicators such as the Effect Size index. Intervention 2: Control group: The women in the control group will receive routine care from the Vulnerable Women's Center. This care is provided in the context of health-focused visits, gynecological examinations, and counseling on high-risk behaviors related to AIDS. After completing the last questionnaire (5 weeks after the last follow-up), in order to enjoy the benefits of the study, an application link will be sent to them and we will answer their questions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mobina Moghassemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kosar dormitory, Mohtasham Ave, No 15 Piroozi street, Sari, Mazandaran.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4818899795</zip>
        <telephone>+98 11 3311 3641</telephone>
        <email>m.moghssmi@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Zeinab Hamzehgardeshi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nasibeh Nursing and Midwifery Faculty, Amir Mazandarani Street</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48431-63181</zip>
        <telephone>009833367342</telephone>
        <email>z.hamzehgardeshi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Iranian nationality
Fluency in Persian
Be part of a vulnerable group of women
Literacy for reading and writing
Has a smartphone and the ability to use it</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>women with acute psychiatric disorders such as schizophrenia (Inserted in the health record)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B97.7</hc_code>
      <hc_code>A63.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Papillomavirus as the cause of diseases classified elsewhere</hc_keyword>
      <hc_keyword>Anogenital (venereal) warts</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>This intervention is based on improving the knowledge of human papillomavirus as a first outcome and promoting the attitude and practice of vulnerable women as a secondary outcome through the mobile application. The content of the application has been prepared by a master's student in midwifery counseling. The research team includes a reproductive health specialist, a reproductive epidemiologist, a sexual health specialist, a psychiatrist, and a midwifery counseling student. After randomly assigning, the intervention group receives the application installation link, and after installing the application on the smartphone, users self-learning for a month. After a month, the application is automatically deactivated and users' access to the app content is cut off. Educational objectives are classified into three areas: affective, psychomotor, and cognitive. In the field of cognition, users are expected to learn about the nature of the HPV virus, its abbreviation, how it is transmitted, its prevalence in vulnerable women, preventive behaviors, the HPV vaccine, and high-risk behaviors after one month. In the field of ​affective, participants are expected to become familiar with common but incorrect beliefs and attitudes and replace them with the right attitudes.In the field of psychomotor, we expect vulnerable women to express behavioral goals that they have learned cognitively about preventive behaviors as behavioral intentions or to seek prevention and treatment if they have a midwife or specialist. The training framework will be implemented through this software in the method of repeated learning. In this context, users will receive a single content using a variety of methods, in simple language, understandable to the target group, and attractive to gradually reinforce the behavioral intent in them. The educational content before loading on the application will be evaluated by the panel of experts, scientifically, literary, and the opinion of the same audience group. Post-loading evaluation: Educational content after loading on the application by two groups of hardware technicians and the matched audience group is evaluated. The effect of the application on improving the outcome (knowledge about human papillomavirus) will be calculated through indicators such as the Effect Size index.</i_keyword>
      <i_keyword>Control group: The women in the control group will receive routine care from the Vulnerable Women's Center. This care is provided in the context of health-focused visits, gynecological examinations, and counseling on high-risk behaviors related to AIDS. After completing the last questionnaire (5 weeks after the last follow-up), in order to enjoy the benefits of the study, an application link will be sent to them and we will answer their questions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knowledge about human papillomavirus. Timepoint: At the time of enrollment - immediately after the intervention - five weeks after the intervention. Method of measurement: Questionnaire of knowledge, attitude, practice about human papillomavirus.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Attitudes about human papillomavirus. Timepoint: At the time of enrollment - immediately after the intervention - five weeks after the intervention. Method of measurement: Questionnaire of knowledge, attitude, practice about human papillomavirus.</sec_outcome>
      <sec_outcome>Practice about human papillomavirus. Timepoint: At the time of enrollment - immediately after the intervention - five weeks after the intervention. Method of measurement: Questionnaire of knowledge, attitude, practice about human papillomavirus.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-12</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Vice chancellor for research, Mazandaran University of Medical Sciences ,Moalem Square, Sari, Mazandaran, Iran Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
